PHYSIOLOGICAL PROBLEMS FOLLOWING OPEN OPERATION ON THE MITRAL VALVE.

L. A. Brewer,C. Coggin,E. Wareham

Abstract:

What problem does this paper attempt to address?

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

Qiwen Yang,Hui Zhang,Yao Wang,Zhipeng Xu,Ge Zhang,Xinxin Chen,Yingchun Xu,Bin Cao,Haishen Kong,Yuxing Ni,Yunsong Yu,Ziyong Sun,Bijie Hu,Wenxiang Huang,Yong Wang,Anhua Wu,Xianju Feng,Kang Liao,Yanping Luo,Zhidong Hu,Yunzhuo Chu,Juan Lu,Jianrong Su,Bingdong Gui,Qiong Duan,Shufang Zhang,Haifeng Shao,Robert E. Badal

DOI: https://doi.org/10.1186/s12879-017-2296-x

IF: 3.7

2017-01-01

BMC Infectious Diseases

Abstract:Background The objective of this study was to investigate the distribution and susceptibility of aerobic and facultative Gram-negative bacilli isolated from Chinese patients with UTIs collected within 48 h (community acquired, CA) or after 48 h (hospital acquired, HA) of hospital admission. Methods From 2010 to 2014, the minimum inhibitory concentrations (MICs) of 12 antibiotics for 4,332 aerobic and facultative Gram-negative bacilli, sampled in 21 hospitals in 16 cities, were determined by the broth microdilution method. Results Enterobacteriaceae composed 88.5% of the total isolates, with Escherichia coli ( E. coli ) (63.2%) the most commonly isolated species, followed by Klebsiella pneumoniae ( K. pneumoniae ) (12.2%). Non- Enterobacteriaceae accounted for only 11.5% of all isolates and included mainly Pseudomonas aeruginosa ( P. aeruginosa ) (6.9%) and Acinetobacter baumannii ( A. baumannii ) (3.3%). Among the antimicrobial agents tested, the susceptibility rates of E.coli to the two carbapenems, ertapenem and imipenem as well as amikacin and piperacillin-tazobactam ranged from 92.5 to 98.7%. Against K. pneumonia, the most potent antibiotics were imipenem (92.6% susceptibility), amikacin (89.2% susceptibility) and ertapenem (87.9% susceptibility). Although non- Enterobacteriaceae did not show high susceptibilities to the 12 common antibiotics, amikacin exhibited the highest in vitro activity against P. aeruginosa over the 5-year study period, followed by piperacillin-tazobactam, imipenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin. The Extended Spectrum Beta-Lactamase (ESBL) rates decreased slowly during the 5 years in E. coli from 68.6% in 2010 to 59.1% in 2014, in K. pneumoniae from 59.7 to 49.2%, and in Proteus mirabilis ( P. mirabilis ) from 40.0 to 26.1%. However, the ESBL rates were different in 5 regions of China (Northeast, North, East, South and Middle-China). Conclusion E. coli and K. pneumonia were the major pathogens causing UTIs and carbapenems and amikacin retained the highest susceptibility rates over the 5-year study period, indicating that they are good drug choices for empirical therapies, particularly of CA UTIs in China.
Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Juan Chen,Qiqiang Liang,Xinyi Chen,Jing Wu,Yanchao Wu,Gaoqin Teng,Man Huang

DOI: https://doi.org/10.2147/IDR.S350976

2022-01-01

Infection and Drug Resistance

Abstract:Purpose: Ceftazidime/avibactam (CAZ/AVI) monotherapy and polymyxin B-based combination therapy are currently two treatment options for patients with carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection; however, few studies have contrasted the relative efficacy of the two antibiotic regimens. The purpose of this study was to compare the effectiveness of CAZ/AVI and polymyxin B against CRPA infection and analyze the independent predictors of 30-day mortality or survival. Patients and Methods: This single-center retrospective observational study included patients with CRPA infection treated with CAZ/AVI or polymyxin B between January 2018 and December 2020. The primary outcomes were the 14-day and 30-day mortality. The secondary outcomes were in-hospital mortality and bacterial clearance. Baseline characteristics and outcomes were compared between the two groups, and COX regression analysis was used to identify predictors of 30-day mortality. Results: A total of 136 patients with CRPA infection were enrolled, including 51 patients in the CAZ/AVI group and 85 patients in the polymyxin B group. The 14-day mortality (5.9% vs 27.1%, p=0.002), 30-day mortality (13.7% vs 47.1%, p<0.001) and in-hospital mortality (29.4% vs 60.0%, p=0.001) in the CAZ/AVI group were significantly lower than the polymyxin B group. The bacterial clearance rate (45.1% vs 12.9%, p<0.001) in the CAZ/AVI group were higher than in the polymyxin B group. After adjustment by propensity score matching, the CAV/AVI group still had lower 30-day mortality (14.3% vs 42.9%, p=0.018) and higher bacterial clearance rate (42.9% vs 14.3%, p=0.018) than the polymyxin B group. The multivariate COX analysis showed that the age was identified as independent predictor of 30-day mortality while CAZ/AVI therapy and central venous catheterization emerged as independent predictors of 30-day survival. Conclusion: CAZ/AVI therapy was superior to polymyxin B therapy for patients with CRPA infection, and provided significant survival benefits, but further larger studies were needed to substantiate our findings.
Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

Liyuan Peng,Zhongheng Zhang,Xueyan Qi,Yanjun Zhong,Tongwen Sun,Lvlin Chen,Junchen Zhu,Xiangui Lv,Penglin Ma

DOI: https://doi.org/10.3389/fmed.2024.1400757

IF: 3.9

2024-01-01

Frontiers in Medicine

Abstract:BackgroundSome cohort studies have explored the effects and safety of polymyxin B (PMB) in comparison to other antibiotics for the treatment of nosocomial infections, yielding inconsistent results. This systematic review aims to explore the effectiveness and safety of PMB and compared it with other antibiotics.MethodsA systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science, searching specific terms to identify quantitative cohort studies or RCTs that compared the effects of PMB with other antibiotics in terms of their efficacy and safety. The Newcastle–Ottawa Scale (NOS) was conducted to evaluate the risk of bias of observational studies. Odds ratios with 95% confidence intervals were used for outcome assessment. We evaluated heterogeneity using the I2 test.ResultsA total of 22 observational trials were included in the analysis. The PMB group had a higher mortality rate compared to the control group (odds ratio: 1.84, 95% CI: 1.36–2.50, p<0.00001, I2 = 73%). while, the ceftazidime-avibactam group demonstrated a distinct advantage with lower mortality rates, despite still exhibiting high heterogeneity (odds ratio 2.73, 95% confidence interval 1.59–4.69; p = 0.0003; I2 = 53%). Additionally, the PMB group had a lower nephrotoxicity rate compared to the colistin group but exhibited high heterogeneity in the results (odds ratio 0.58, 95% CI 0.36–0.93; p = 0.02; I2 = 73%).ConclusionIn patients with nosocomial infections, PMB is not superior to other antibiotics in terms of mortality, specifically when compared to ceftazidime-avibactam. However, PMB demonstrated an advantage in terms of nephrotoxicity compared to colistin.
Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score–Matched, Retrospective Cohort Analysis

Niyati H Shah,Kathleen A Shutt,Yohei Doi

DOI: https://doi.org/10.1093/ofid/ofab102

2021-03-06

Open Forum Infectious Diseases

Abstract:Abstract Background Ampicillin-ceftriaxone (AC) has emerged as an alternative antibiotic regimen for enterococcal infective endocarditis (EIE) with reduced toxicity compared with ampicillin-gentamicin (AG), but evidence regarding its success in reducing EIE-associated death in the United States is limited. Methods We conducted a retrospective, propensity score–matched cohort analysis of EIE patients treated with AC or AG between 2010 and 2017 at 3 hospitals in Pittsburgh, Pennsylvania. We assessed all-cause 90-day mortality as the primary outcome and in-hospital mortality, length of hospital stay, hospital readmissions, adverse events, and relapse of bacteremia as the secondary outcomes. Results A total of 190 patients with EIE (100 treated with AC and 90 with AG) were included. Ninety-day mortality was significantly higher with AC than AG (21% vs 8%; P = .02). After propensity score matching, 56 patients in each group remained for the outcomes analysis. Documented aminoglycoside resistance, presence of annular or aortic abscess, and complete pacemaker removal were the significantly different variables between the 2 matched cohorts. We observed no statistically significant difference in 90-day mortality between the 2 treatment groups (11% vs 7%; P = .55). Adverse events were more common in patients treated with AG (25 vs 39; P = .0091), and more patients in the propensity score–matched AG cohort switched antibiotic regimens than in the AC group (10% vs 49%; P < .0001). Conclusions Patients treated with AC demonstrate no significant differences in mortality, treatment failure, or bacteremia relapse compared with AG in a propensity score–matched EIE cohort.

immunology,infectious diseases,microbiology
The effects of empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: A systematic review and network meta-analysis of randomized controlled trials

Maryam Ghadimi,Reed A.C. Siemieniuk,Gordon Guyatt,Mark Loeb,Afeez Abiola Hazzan,Danial Aminaei,Huda Gomaa,Ying Wang,Liang Yao,Arnav Agarwal,John Basmaji,Alexandre Grant,William S.H. Kim,Giancarlo Alvarado-Gamarra,Valery Likhvantsev,João Pedro Lima,Shahrzad Motaghi,Rachel Couban,Behnam Sadeghirad,Romina Brignardello-Petersen

DOI: https://doi.org/10.1016/j.cmi.2024.05.017

IF: 13.31

2024-06-01

Clinical Microbiology and Infection

Abstract:Background The optimal empiric antibiotic regimen for non-ventilator-associated hospital-acquired pneumonia (HAP) is uncertain. Objectives To compare alternative empiric antibiotic regimens in HAP using a network meta-analysis (NMA). Methods Data sources: Medline, EMBASE, Cochrane CENTRAL, Web of Science, and CINAHL from database inception to July 06, 2023. Study eligibility criteria Randomized controlled trials (RCT). Participants Adults with clinical suspicion of HAP. Intervention Any empiric antibiotic regimen versus another, placebo, or no treatment. Assessment of risk of bias Paired reviewers independently assessed risk of bias using a modified Cochrane tool for assessing risk of bias in randomized trials. Methods of data analysis Paired reviewers independently extracted data on trial and patient characteristics, antibiotic regimens, and outcomes of interest. We conducted frequentist random-effects NMAs for treatment failure and all-cause mortality and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results 39 trials proved eligible. 30 RCTs involving 4,807 participants found low certainty evidence that piperacillin-tazobactam (RR compared to all cephalosporins: 0.65; 95% CI: 0.42, 1.01) and carbapenems (RR compared to all cephalosporins: 0.77; 95% CI: 0.53, 1.11) might be among the most effective in reducing treatment failure. The findings were robust to the secondary analysis comparing piperacillin-tazobactam vs antipseudomonal cephalosporins or antipseudomonal carbapenems vs antipseudomonal cephalosporins. 11 RCTs involving 2,531 participants found low certainty evidence that ceftazidime and linezolid combination may not be convincingly different from cephalosporin alone in reducing all-cause mortality. Evidence on other antibiotic regimens is very uncertain. Data on other patient-important outcomes including adverse events was sparse, and we did not perform network or pairwise meta-analysis. Conclusions For empiric antibiotic therapy of adults with HAP, piperacillin-tazobactam might be among the most effective in reducing treatment failure in HAP. Empiric MRSA coverage may not exert additional benefit in reducing mortality in HAP. Registration PROSPERO (CRD 42022297224)

infectious diseases,microbiology
Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients

Sydney VanDorf,Prakash Shah,Christine N Yost

DOI: https://doi.org/10.1177/10600280231205219

Abstract:Background: The preferred carbapenem for treatment of infections caused by extended spectrum beta-lactamase-producing Enterobacterales (ESBL-E) in critically ill patients is debated. Objective: The purpose of this study was to evaluate the difference in clinical failure between ertapenem and meropenem for treatment of ESBL-E bacteremia in critically ill patients. Of concern is ertapenem use in hypoalbuminemia given the potential for higher drug clearance. Methods: This retrospective, matched cohort study compared critically ill patients treated with ertapenem or meropenem for ESBL-E bacteremia between October 2016 and August 2022. Patients were matched on age, sex, lowest albumin, and in a 1:2 ratio of ertapenem to meropenem. The primary outcome, clinical failure, was a composite of 30-day mortality, antibiotic escalation, and microbiological failure. Secondary outcomes included all-cause readmission and development of superinfection. Results: Of 54 patients, 18 received ertapenem and 36 meropenem. Most had a urinary infection source (55.6% vs 41.7%, P = 0.393). There was no difference in clinical failure (50.0% vs 38.9%, P = 0.436). Ertapenem patients had antibiotic escalation more often (33.3% vs 2.8%, P = 0.002). There was no difference in 30-day mortality (11.1% vs 27.8%, P = 0.298), microbiological failure (27.8% vs 11.1%, P = 0.142), all-cause readmission (22.2% vs 13.9%, P = 0.461), or development of superinfection (11.1% vs 13.9%, P = 1.000). Conclusion and relevance: There was no difference in clinical failure in a small, retrospective cohort of critically ill patients receiving ertapenem or meropenem for ESBL-E bacteremia. Ertapenem may be appropriate in some critically ill and hypoalbuminemic patients, though additional data are needed.
Prospective evaluation of single‐dose aminoglycosides for treatment of complicated cystitis in the emergency department

Jordan E. Jenrette,Kyle Coronato,Matthew A. Miller,Kyle C. Molina,Alexander Quinones,Gabrielle Jacknin

DOI: https://doi.org/10.1111/acem.14886

2024-03-08

Academic Emergency Medicine

Abstract:Background Antimicrobial resistance among Enterobacterales continues to be a growing problem, particularly in those with urinary infections. Previous studies have demonstrated safety and efficacy with the use of single‐dose aminoglycosides in uncomplicated cystitis. However, data in complicated infections are limited. Single‐dose aminoglycosides may provide a convenient alternative for those with or at risk for resistant pathogens causing complicated urinary infections, especially when oral options are unavailable due to resistance, allergy, intolerance, or interactions with other medications. This study evaluated the safety and effectiveness of single‐dose aminoglycosides in treatment of complicated cystitis in the emergency department (ED). Methods This was a multicenter, prospective study performed between July 2022 and March 2023 of patients who met criteria for complicated cystitis and were otherwise stable for discharge at an academic ED. Primary outcomes were clinical or microbiologic failure within 14 days of treatment. Safety was assessed by review of adverse events. Descriptive statistics were used. Results Thirteen patients were included. Complicating factors were male sex (n = 4), kidney stone (n = 2), urinary catheter (n = 6), recent urologic procedure (n = 1), urinary hardware (n = 1), antibiotic allergy precluding use of alternate oral options (n = 4), immunocompromised status (n = 2), and <1‐year history of multidrug‐resistant organisms on urine culture (n = 8). Eleven patients (85%) had positive urine cultures in the preceding 12 months with no oral antimicrobial option. Eight patients (62%) received amikacin (median dose 15 mg/kg), four patients (31%) received gentamicin (median dose 5 mg/kg), and one patient (8%) received tobramycin (5 mg/kg) for treatment. Ten patients (77%) reported resolved urinary symptoms after treatment and 11 patients (85%) reported no new urinary symptoms since discharge. No patient required hospital admission for treatment failure, and no adverse events were noted. Conclusions Single‐dose aminoglycosides appear to be a reasonably effective and safe treatment for complicated cystitis, which avoided hospital admission in this cohort.

emergency medicine
[Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives]

Akira Yamamoto,Koichi Yamasaki

DOI: https://doi.org/10.3143/geriatrics.52.153

Abstract:Background: An increasing incidence of extended-spectrum β-lactamase (ESBL-) producing Escherihia Coli poses a difficult problem for clinicians to establish an optimal strategy for the effective antibiotic treatment of urinary tract infections (UTI). Methods: (1) Fosfomycin/minocycline (FOM/MINO) or rifampicin/sulfamethoxazole-trimethoprim (RFP/ST) combinations and (2) levofloxacin (LVFX) alone were used as an internal medication, and (3) cefoperazone/sulbactam (CPZ/SBT) and (4) meropenem (MEPM) were administered through intravenous injection. The selection of antibiotics was done empirically, according to the history and severity of illness and urinary findings, and the presence of comobidities. The efficacy of the treatment was determined by the absence of any pathogenic bacteria from a urinary culture after treatment. Results: ESBL-producing and LVFX resistant non-ESBL producing E. coli were detected by an initial urinary culture in 33 and 10%, respectively, of the specimens before treatment. All the ESBL-producing E. Coli colonies were resistant against LVFX. The efficacy of the treatment was 9/11 (82%) in the FOM/MINO-RFP/ST group, 9/14 (64%) in the LVFX group, 9/16 (56%) in the CPZ/SBT group, and 19/27 (70%) in the MEPM group. In the FOM/MINO・RFP/ST group, ESBL-producing E. Coli were detected in the urine before treatment in 5 out of 16 patients and those E. coli disappeared after treatment in all 5 patients. In the LVFX group, the drug was changed to MEPM in 6 out of 15 patients soon after the presence of ESBL-producing/LVFX resistant E. Coli was identified by a urinary culture. In the CPZ/SBT group, ESBL-producing and/or LVFX-resistant E. coli disappeared in 4 out of 6 cases, while they were newly found in post-treatment urine cultures in 2 patients. In the MEPM group, 15 out of 28 patients initially had ESBL-producing/LVFX resistant E. Coli and those drug-resistant E. Coli disappeared from their urine after treatment in all patients. The drug susceptibility test of the urinary culture from all the patients with UTI showed CPZ/SBT-resistant colonies to be found in 19 out of 32 specimens, while AMPC/CVA-resistant ones were found in 9 out of 32 of ESBL-producing E. Coli. Conclusions: Our present study demonstrates that FOM/MINO or ST combinations were effective in the treatment of ESBL-producing E. Coli in mild cases of UTI and MEPM in severe cases. When using β-lactam/β-lactamase inhibitor combinations, the effect should be ascertained by examining post-treatment urinary specimens, because of the presence of ESBL-producing E. Coli strains which are resistant to those antibiotics.
Allergic colitis in preterm infants. 859

Marita A. D’Netto,I. Knox,V. Herson,J. Hyams,C. Justinich

DOI: https://doi.org/10.1203/00006450-199704001-00879

IF: 3.953

1997-04-01

Pediatric Research

Abstract:Allergic colitis is seen in young infants as a response to sensitization to cow's milk, soy protein or from dietary antigens transmitted through breast milk. The incidence of allergic colitis in full-term infants is estimated to be 0.5 to 1%. Prematurity is one of a number of risk factors identified. Signs and symptoms of allergic colitis can mimic necrotizing enterocolitis(NEC); therefore, allergic colitis may be under-recognized. This entity has received little attention in the literature. Aim: To review our experience of allergic colitis in preterm infants. Methods: We carried out a 7 year retrospective review of all infants less than 37 weeks gestation with allergic colitis identified by sigmoidoscopic biopsy of the colon demonstrating eosinophilia(>20 per high power field, or with intraepithelial eosinophils). Results: From a total of 14 preterm infants who underwent sigmoidoscopy, 7/14 (50%) were diagnosed with allergic colitis, with increased eosinophils on mucosal biopsy. Sigmoidoscopy was well tolerated under conscious sedation; no complications were reported. Gestational age at birth ranged from 24-36 wks; corrected gestational age at diagnosis was 33 to 42 weeks, (median 36 wks). Symptoms included hematochezia(2/7), emesis/feeding intolerance(4/7), feeding aversion(5/7), irritability(3/7), failure to thrive(3/7). One infant presented with diarrhea leading to hypovolemic shock. The majority of infants had received antibiotics and TPN for suspected NEC. After diagnosis symptoms resolved on semi-elemental formula. Conclusions: Allergic colitis occurs in preterm infants, often without characteristic symptoms. Only a minority have gross blood per rectum. Symptoms often mimic NEC or sepsis, leading to unnecessary antibiotic treatment and fasting. Prompt evaluation with sigmoidoscopy and biopsy is well tolerated and allows for early diagnosis and appropriate dietary management.
Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis

Lorenzo Onorato,Ilaria de Luca,Annabella Salvati,Caterina Monari,Nicola Coppola

DOI: https://doi.org/10.1007/s15010-024-02447-y

2024-12-06

Infection

Abstract:Background The best treatment for bloodstream infections (BSI) due to chromosomal AmpC (c-AmpC) producing Enterobacterales is not clearly defined. Objectives To describe the clinical and microbiological outcomes of patients treated with piperacillin/tazobactam, cefepime or carbapenems for bloodstream infections (BSIs) due to c-AmpC beta-lactamase-producing strains. Data sources We searched MEDLINE, the Cochrane Library and EMBASE to screen original reports published up to January 2024. Study eligibility criteria RCTs and observational studies investigating all-cause mortality, clinical failure, microbiological failure or rate of ADRs of patients treated with piperacillin/tazobactam, cefepime or carbapenems. Participants Patients with bloodstream infections due to c-AmpC producing bacteria. Interventions Piperacillin/tazobactam, cefepime or carbapenems as targeted treatment. Assessment of risk of bias We used the Cochrane Risk of Bias Tool for RCTs, and the Newcastle Ottawa scale for observational studies. Methods of data synthesis We conducted a meta-analysis pooling Risk ratios (RRs) through random effect models. Results We screened 1,720 original reports, and 20 studies (1 RCTs, 1 case-control study, 18 cohort studies) were included in the analysis, for a total of 2,834 patients. When comparing piperacillin/tazobactam with alternative treatments (cefepime or carbapenems), no significant difference in mortality rate was observed between the treatment groups (RR: 1.1; 95% CI: 0.76–1.58, p = 0.61), while an higher rate of microbiological failure (RR: 1.80; 95% CI: 1.15–2.82, p = 0.01) and clinical failure (RR: 1.54; 95% CI: 1.00-2.40, p = 0.05) was observed among patients receiving piperacillin/tazobactam. No difference was observed in microbiological and clinical failure rate among patients treated with cefepime or carbapenems, with a lower mortality rate in those receiving cefepime (RR: 0.74; 95% CI: 0.59–0.94, p = 0.014). Conclusions Cefepime represents an excellent alternative to carbapenems for BSI due to AmpC-producing strains, whereas piperacillin/tazobactam is associated with a higher rate of clinical and microbiological failure. There is an urgent need for randomized clinical trials that aim to define the best carbapenem-sparing strategy in these infections.

infectious diseases
Comparison of the Relative Efficacy of Β-Lactam/β-lactamase Inhibitors and Carbapenems in the Treatment of Complicated Urinary Tract Infections Caused by Ceftriaxone-Non-susceptible Enterobacterales: a Multicentre Retrospective Observational Cohort Study.

Liang Chen,Jie Hua,Shu-Jie Hong,Chen-Yang Yuan,Ruo-Chen Jing,Xuan-Yu Luo,Hao-Wen Xue,Yue,Xiao-Pu He

DOI: https://doi.org/10.1093/jac/dkac448

2023-01-01

Journal of Antimicrobial Chemotherapy

Abstract:BACKGROUND:Treating complicated urinary tract infections (cUTIs) caused by ESBL-producing Enterobacterales represents a significant clinical challenge. The present study was thus developed to explore the relative efficacy of β-lactam/β-lactamase inhibitors (BLBLIs) and carbapenems for the treatment of hospitalized patients suffering from cUTIs caused by BLBLI-susceptible ceftriaxone-non-susceptible Enterobacterales.METHODS:Data from 557 patients from four Chinese teaching hospitals diagnosed with cUTIs caused by ceftriaxone-non-susceptible Enterobacterales from January 2017 to May 2022 were retrospectively assessed.RESULT:The 30 day rate of treatment failure, defined by unresolved symptoms or mortality, was 10.4% (58/557). Independent predictors of 30 day treatment failure included immunocompromised status, bacteraemia, septic shock, lack of infection source control and appropriate empirical treatment. When data were controlled for potential confounding variables, BLBLI treatment exhibited a comparable risk of 14 day (OR 1.61, 95% CI 0.86-3.00, P = 0.133) and 30 day treatment failure (OR 1.45, 95% CI 0.66-3.15, P = 0.354) relative to carbapenem treatment for the overall cohort of patients. In contrast, BLBLI treatment in immunocompromised patients was associated with an elevated risk of both 14 day (OR 3.18, 95% CI 1.43-7.10, P = 0.005) and 30 day treatment failure (OR 3.06, 95% CI 1.07-8.80, P = 0.038) relative to carbapenem treatment.CONCLUSIONS:These results suggested that carbapenem treatment may be superior to BLBLI treatment for immunocompromised patients suffering from cUTIs caused by ceftriaxone-non-susceptible Enterobacterales species. However, these results will need to be validated in appropriately constructed randomized controlled trials to ensure appropriate patient treatment.
25 years of experience on the management of enterococcal infective endocarditis an observational study

Lorenz Schubert,Rui-Yang Chen,Matthias Weiss-Tessbach,Richard Kriz,Markus Obermüller,Matthias Jackwerth,Wolfgang Barousch,Heinz Burgmann,Manuel Kussmann,Ludwig Traby

DOI: https://doi.org/10.1007/s15010-024-02407-6

2024-10-15

Infection

Abstract:Purpose: As they are effective and well tolerated, aminopenicillins are still the cornerstone for the treatment of enterococcal infections. Current treatment guidelines for infective endocarditis (IE) recommend combination treatments, which carry a higher risk of adverse effects and are based on limited in vitro and experimental data. The aim of this study was therefore to evaluate the treatments of enterococcal IE in real-life practice. Methods: A total of 4121 episodes of enterococcal bloodstream infections, occurring between 1994 and 2019, were screened for the evidence of IE. Baseline characteristics, risk factors for complicated infections and treatment information were assessed and analyzed using Cox regression analysis. Results: Overall, 80 (3.9%) IE episodes were identified of which 78 were included in the final analysis. Treatment regimens in our cohort comprised aminopenicillin-monotherapy (n = 20), teicoplanin-monotherapy (n = 26), other monotherapies (OMT) (n = 8), as well as combinations of ampicillin plus daptomycin (n = 8), ampicillin plus gentamicin (n = 4) or other combinations (n = 9). Overall mortality at 28-days was low (9 of 75) and increased to (19 of 75) after 6-months. Frequency of moderate to severe valve regurgitation (p = 0.89), or signs of uncontrolled infection (p = 0.5) and vegetation size ≥ 10 mm (p = 0.11) were similar in the treatment groups. None of the treatment groups was associated with increased hazard for IE-related mortality. Conclusions: This retrospective study complements previous evidence, demonstrating that monotherapy regimens may be a suitable and effective option for the treatment of IE and supports the need for a prospective evaluation of aminopenicillin-monotherapy for initial and subsequent therapy in these patients.
2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)

Andrew Scott Purdy,Zach Howe,Armisha Desai

DOI: https://doi.org/10.1093/ofid/ofad500.2406

2023-11-27

Open Forum Infectious Diseases

Abstract:Abstract Background Recent guidance from IDSA recommends meropenem for treatment of organisms at moderate-high risk for inducible chromosomal AmpC β-lactamase hyperproduction (AmpC organisms) with a cefepime minimum inhibitory concentration (MIC) of 4-8 mCg/mL (susceptible dose-dependent or S-DD).1 This runs contrary to pharmacokinetic/pharmacodynamic data and Clinical and Laboratory Standards Institute (CLSI) M100 guidance, which considers organisms ≥ 16 mCg/mL resistant.2 The purpose of this study is to evaluate the clinical efficacy of cefepime versus meropenem for the treatment of infections caused by AmpC organisms with a S-DD cefepime MIC. Methods This was a retrospective study evaluating patients treated within Indiana University Health from 2015-2022. All cefepime S-DD AmpC isolates were included. Exclusion criteria were < 48 hours of treatment, multiple days of therapy with another active agent, inadequate dosing, extended spectrum β-lactamase (ESBL) co-production, and carbapenem resistance. The primary endpoint of this study was a composite of in-hospital all-cause mortality and antibiotic escalation due to clinical worsening. Secondary endpoints include positive repeat blood cultures within 7 days of treatment initiation, and ESBL or carbapenem resistant organism isolation during or following treatment. Results 355 isolates were screened. 71 patients were included in the final analysis, 43 in the cefepime group and 28 in the meropenem group. Baseline characteristics were not significantly different. Enterobacter cloacae made up 79% of cases. The primary endpoint occurred in 13/43 (30%) of patients on cefepime and 7/28 (25%) of patients on meropenem (P=0.63). Treatment escalation and escalation due to clinical worsening was higher in the cefepime group with 7 (16%) and 6 (14%) incidents respectively compared to none in the meropenem group (P=0.03; P=0.04). No other endpoints, including all-cause mortality, were significantly different between groups. Conclusion Cefepime remains a viable treatment option for ESBL-negative, AmpC organisms with MICs in the S-DD range. Disclosures All Authors: No reported disclosures

immunology,infectious diseases,microbiology
Novel β-lactam antibiotics versus other antibiotics for treatment of complicated urinary tract infections: a systematic review and meta-analysis

Xiang hua Quan,Xin yi Wang,Chun hua Han,Xiao min Xing,Bin Zhang,Huai qin Cang

DOI: https://doi.org/10.3389/fphar.2024.1420170

IF: 5.6

2024-10-11

Frontiers in Pharmacology

Abstract:Background: Novel β-lactam antibiotics as well as other kinds of antibiotics have been used to treat complicated urinary tract infections (cUTIs); however, their efficacy and safety remain controversial. Objective: We conducted a systematic review with meta-analysis to explore the efficacy and safety of novel β-lactam antibiotics versus other antibiotics against cUTIs. Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched systematically from inception through 15 March 2024 for clinical trials comparing novel β-lactam antibiotics with other antibiotics for treatment of cUTIs. Random-effects models were used to evaluate the impact of treatment on the risk ratio (RR) of clinical response, microbiologic response, adverse effects (AEs), serious adverse effects (SAEs). The quality of evidence was evaluated with the Cochrane Risk of Bias assessment tool. The review was registered in INPLASY (INPLASY202440054). Results: Ten randomized controlled trials involving 5, 925 patients met our inclusion criteria. Our meta-analysis revealed that there was no significant difference in overall clinical response (RR = 1.02), AEs (RR = 1.07), SAEs (RR = 1.20) between novel β-lactam antibiotics groups and other antibiotics groups. However, a significant difference was found in a subgroup of clinical cure rates at the end of treatment between novel β-lactam antibiotics groups and carbapenems groups, with low heterogeneity (RR = 1.02). A significant difference was observed in microbiologic response (RR = 1.11). Subgroup analysis revealed a significant difference in microbiologic response between novel BBL/BLS groups and carbapenems groups (RR = 1.13, I 2 = 21%, P = 0.005). Differences was observed between novel BBL/BLS groups and piperacillin/tazobactam sodium groups (RR = 1.21, I 2 = 70%, P = 0.02). Similar results were obtained from subgroup analysis of the difference in microbiologic response between novel β-lactam antibiotics groups and ertapenem groups (RR = 0.92, I 2 = 0, P = 0.01). Conclusion: Novel β-lactam antibiotics had similar overall clinical cure, AEs, SAE, to other antibiotics in the treatment of cUTIs. However, novel β-lactam antibiotics demonstrated superior clinical cure rates compared to carbapenems in a subgroup analysis, and exhibited better microbiologic response than other antibiotics.

pharmacology & pharmacy
Ceftriaxone versus Cefepime or Carbapenems for Definitive Treatment of Low-Risk AmpC-Harboring Enterobacterales Bloodstream Infections in Hospitalized Adults: a Retrospective Cohort Study

Jessica L. Mulbah,Rachel M. Kenney,Robert J. Tibbetts,Anita B. Shallal,Michael P. Veve

DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116557

IF: 2.983

2024-10-15

Diagnostic Microbiology and Infectious Disease

Abstract:Objective To compare outcomes of ceftriaxone to AmpC-stable therapies in patients with bacteremia caused by low-risk AmpC harboring Enterobacterales. Methods IRB-approved, retrospective cohort of hospitalized patients ≥18 years old with Serratia marcescens , Morganella morganii , or Providencia spp. bacteremia from 1/1/2017-2/28/2024. Patients were compared by definitive therapy with ceftriaxone vs AmpC-stable therapy (cefepime, carbapenem). The primary endpoint was 30-day all-cause mortality; secondary endpoints were clinical failure and development of ceftriaxone resistance. Results 163 patients were included; 33.1% received ceftriaxone, 66.9% AmpC-stable therapies. 30-day all-cause mortality was 9.3% ceftriaxone vs 10.1% AmpC stable patients ( P =0.87); ceftriaxone definitive therapy was not associated with 30-day all-cause mortality (adjOR, 0.79; 95%CI, 0.23-2.3). There were no differences in clinical failure (9.3% vs 21.1%, P= 0.059) or relapsing infection (5.6% vs 9.3%, P =0.55) between ceftriaxone and AmpC-stable treated patients. Conclusions Patients treated with definitive ceftriaxone for low-risk AmpC Enterobacterales bacteremia had similar outcomes to AmpC stable therapies.

infectious diseases,microbiology
Antimicrobial Susceptibilities of Clinical Bacterial Isolates from Urinary Tract Infections to Fosfomycin and Comparator Antibiotics Determined by Agar Dilution Method and Automated Micro Broth Dilution

Jamie L Dombach,Nancy Smith,Teresa Kottiri,Alicia M Schiller,Edwin Kamau

DOI: https://doi.org/10.1101/2024.07.25.24311029

2024-07-26

Abstract:Uncomplicated bacteremic urinary tract infections (bUTIs) are common, often caused by Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis, with most encounters treated empirically. As rates of antimicrobial resistance increase, available antibiotic treatment options are dwindling. Novel antibiotics approved for treating bUTIs are limited, leading to a resurgence of interest in older antibiotics, including fosfomycin. In this study, clinical urine samples from patients diagnosed with bUTIs from a military hospital on the Eastern Seaboard of the United States were tested for susceptibility to fosfomycin and comparator antibiotics, including levofloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole (TMS). A total of 1353 nonduplicate bacterial isolates were tested. The majority were Gram-negative, including 605 non-ESBL and 285 ESBL E. coli and 84 non-ESBL and 52 ESBL K. pneumoniae. Fosfomycin susceptibility rates were similar for non-ESBL and ESBL E. coli (95.9% vs 96.1%) and K. pneumoniae (38.1% vs 36.5%). Fosfomycin demonstrated high activity against other Enterobacterales and Gram-positive organisms including Enterobacter faecalis and Staphylococcus aureus. Interestingly, most fosfomycin non-susceptible isolates were susceptible to other first-line bUTI treatment options, and most isolates that were non-susceptible to other first-line bUTI treatment option were susceptible to fosfomycin. ESBL K. pneumoniae isolates were the least susceptible to current first-line treatment options. Fosfomycin Etest demonstrated high sensitivity compared to agar dilution, making it a viable method in resource limited areas. Overall, we demonstrated fosfomycin has high activity against common etiologies that cause bUTIs. Further studies investigating the use of fosfomycin in treating non-E. coli bUTI pathogens, as single or combination therapy, is warranted.

Infectious Diseases (except HIV/AIDS)
Amikacin treatment in urinary tract infection patients: evaluating the risk of acute kidney injury – a retrospective cohort study

Avner Dagan,Danny Epstein,Ami Neuberger,Jonathan Isenberg

DOI: https://doi.org/10.1080/1120009x.2024.2319454

2024-02-20

Journal of Chemotherapy

Abstract:The rise in ESBL-producing and carbapenem-resistant Gram-negative bacterial infections is alarming. Aminoglycosides remain attractive for treating urinary tract infections (UTIs). However, aminoglycosides-associated acute kidney injury (AKI) raises concerns, especially in patients with underlying renal impairment. We conducted a retrospective cohort study to evaluate the risk of AKI in patients with UTI empirically treated with amikacin. Among 395 patients (median age 41.9 years [IQR 28.3–67.1], 342 [86.6%] female), 162 (41.0%) received amikacin and 233 (59.0%) were empirically treated with other antibiotics. AKI incidence was low (5.6%) and not associated with amikacin exposure (OR 0.56, 95% CI 0.22–1.43, p = 0.23), even in those with pre-existing renal impairment or AKI on admission. The clinical outcomes (including cure by the third day, AKI, maximal creatinine, length of stay, mortality, and readmission) did not differ between the groups. Once-daily amikacin may offer a safe UTI treatment option amid increasing multi-drug resistance.

oncology,pharmacology & pharmacy,infectious diseases
Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections

Carrie P Wong,Thomas Delate,Elizabeth Hudson,Julia K Nguyen,Su-Jau Yang,Mariana Abraham

DOI: https://doi.org/10.1186/s12879-021-06458-0

2021-08-16

Abstract:Background: Urinary tract infections (UTI) are often over-diagnosed and over-treated, which can induce and select for resistant pathogens. After observing wide-spread outpatient use of ertapenem, a broad-spectrum antibiotic, a structured antimicrobial stewardship initiative (ASI) to improve appropriate antimicrobial prescribing was undertaken. ASI objectives were to achieve a goal of reducing ertapenem utilization for extended spectrum beta lactamase Enterobacteriaceae (ESBL-EB) UTI by 10% and evaluate the clinical outcomes associated with the ASI. Methods: A pre-to-post cohort study was conducted at a single-center integrated healthcare system between November 1, 2014 and February 26, 2017. An intensive, 90-day, pharmacist-driven, structured ASI was implemented between November 1, 2015 and January 29, 2016. Female patients aged ≥18 years who were treated for an uncomplicated, ESBL-EB urinary tract infection (UTI) were included. Primary outcome was clinical resolution defined as cure, persistence, relapse and recurrence. Secondary outcome measured was monthly ertapenem use expressed as number of days of therapy (DOT)/1000 adjusted patient days (APD). Segmented regression analysis for interrupted time series was performed to estimate ASI intervention effect. Results: A total of 184 patients were included in the study. Ertapenem utilization decreased from 0.0145 DOT/1000 APD in Nov. 2014 to 0.0078 DOT/1000 APD Feb. 2017(p < 0.01). The mean ertapenem DOT declined 19% overall from the pre vs. post intervention periods (32 vs 26, p < 0.01). Frequency of recurrent UTIs between treatments did not significantly differ and no adverse effects were reported in patients treated with aminoglycosides. Conclusions: A structured ASI for uncomplicated ESBL-EB UTI was associated with a clinically meaningful decrease in ertapenem utilization and once-daily, 5-day aminoglycoside treatment was well-tolerated.
Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-onset Clostridioides difficile Infection

Eric Wombwell,Allison Rosa

DOI: https://doi.org/10.1016/j.clinthera.2024.02.011

Abstract:Purpose: Urinary tract infection (UTI) is the second most common indication for antibiotic therapy among inpatients in the United States. Ceftriaxone, a third-generation cephalosporin, is habitually chosen to treat inpatient UTIs due to familiarity, cost, and perceived safety. However, third-generation cephalosporins increase the risk of health care facility-onset Clostridioides difficile infection (HOCDI) more than any other antibiotic group, while no statistical risk exists for first-generation cephalosporins. Recent evidence comparing Enterobacterales susceptibility for first- and third-generation cephalosporins in urinary specimens in the United States is limited. This analysis assessed the comparative activity of cefazolin and ceftriaxone for Enterobacterales urinary isolates and incidence of HOCDI to determine the usefulness of cefazolin as an empirical agent to manage inpatient UTI and limit ceftriaxone collateral damage. Methods: This was a retrospective single-center observational study. Microbiologic susceptibility data were analyzed for Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis urinary specimens taken from adult inpatients admitted from January 1, 2022, to December 31, 2022. Primary outcome was incidence of E coli, K pneumoniae, and P mirabilis susceptibility to cefazolin in uncomplicated UTI (MIC <16 µg/mL). Secondary outcomes include susceptibility for complicated UTI and HOCDI risk associated with cefazolin and ceftriaxone. Findings: A total of 1150 urine samples were identified as E coli, K pneumoniae, and P mirabilis in 2022. Susceptibility to cefazolin was observed in 1064 (92.5%) of 1150 isolates using the MIC breakpoint for uncomplicated UTI and to ceftriaxone in 1115 (97.0%) of 1150 isolates (P < 0.001). From 2016 to 2022, either cefazolin or ceftriaxone was administered in 26,462 inpatient admissions, with HOCDI diagnoses occurring in 89 admissions. HOCDI developed in 78 admissions (0.40%) with ceftriaxone exposure, and 11 cases (0.15%) developed in cefazolin-exposed admissions (adjusted odds ratio, 2.44; 95% CI, 1.25-4.76; P < 0.001). Implications: Cefazolin exhibits high susceptibility for uropathogens commonly implicated in cases of uncomplicated UTI, the most common UTI diagnosis among inpatients. Although ceftriaxone shows a higher susceptibility rate against these common uropathogens, it more than doubles the risk for HOCDI compared with cefazolin. For institutions evaluating opportunities to reduce ceftriaxone use to limit associated collateral damage such as HOCDI, use of cefazolin for uncomplicated UTI may be evaluated by using local susceptibility data.
Penicillin versus anti-staphylococcal beta-lactams for penicillin-susceptible Staphylococcus aureus blood stream infections: a retrospective cohort study

Gemma Reynolds,Simeon Crawford,Jose Cuenca,Niladri Ghosh,Peter Newton

DOI: https://doi.org/10.1007/s10096-021-04330-2

Abstract:The objective of the study is to assess the efficacy and tolerability of penicillins compared to anti-staphylococcal beta-lactams for treatment of penicillin-susceptible Staphylococcus aureus bloodstream infections (PSSA BSI). A retrospective cohort study was conducted of 140 sequential PSSA BSI presenting to a local health district (90 cases included). Penicillin susceptibility was confirmed by disc diffusion, Vitek® and Nitrocefin beta-lactamase methods. Clinical information regarding comorbidities and infection complexity was recorded. Antibiotic choice, dosage and duration were reviewed. Outcomes were compared according to the definitive treatment with either penicillin or ASBLs. The primary outcome was 30-day mortality. Secondary outcomes included renal injury, microbiological relapse and treatment tolerability. Ninety patients met inclusion criteria and were included in subsequent analysis. Of PSSA BSI, 69% were community acquired. Eighty-two percent had complex PSSA infections. The average duration of bacteraemia was 2.8 days (SD = 1.8 days). Sixty-six patients received definitive penicillin treatment, with a mean of 3.5 days of empiric antibiotics prior to penicillin. Twenty-four patients received definitive ASBL treatment (11 cefazolin, 13 flucloxacillin). There was no difference in 30-day mortality between groups (p = 1). There was no difference in renal injury (p > 0.5), hospital length of stay (p = 0.59) or microbiological relapse within 1 year (p = 0.17). Penicillin treatment was well tolerated. Our data supports penicillin as a suitable and well-tolerated alternative to ASBL in managing complex PSSA BSI.

PHYSIOLOGICAL PROBLEMS FOLLOWING OPEN OPERATION ON THE MITRAL VALVE.

Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score–Matched, Retrospective Cohort Analysis

The effects of empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: A systematic review and network meta-analysis of randomized controlled trials

Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients

Prospective evaluation of single‐dose aminoglycosides for treatment of complicated cystitis in the emergency department

[Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives]

Allergic colitis in preterm infants. 859

Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis

Comparison of the Relative Efficacy of Β-Lactam/β-lactamase Inhibitors and Carbapenems in the Treatment of Complicated Urinary Tract Infections Caused by Ceftriaxone-Non-susceptible Enterobacterales: a Multicentre Retrospective Observational Cohort Study.

25 years of experience on the management of enterococcal infective endocarditis an observational study

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)

Novel β-lactam antibiotics versus other antibiotics for treatment of complicated urinary tract infections: a systematic review and meta-analysis

Ceftriaxone versus Cefepime or Carbapenems for Definitive Treatment of Low-Risk AmpC-Harboring Enterobacterales Bloodstream Infections in Hospitalized Adults: a Retrospective Cohort Study

Antimicrobial Susceptibilities of Clinical Bacterial Isolates from Urinary Tract Infections to Fosfomycin and Comparator Antibiotics Determined by Agar Dilution Method and Automated Micro Broth Dilution

Amikacin treatment in urinary tract infection patients: evaluating the risk of acute kidney injury – a retrospective cohort study

Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections

Comparison of Cefazolin and Ceftriaxone Enterobacterales Susceptibilities for Inpatient Treatment of Urinary Tract Infections and Risk of Hospital-onset Clostridioides difficile Infection

Penicillin versus anti-staphylococcal beta-lactams for penicillin-susceptible Staphylococcus aureus blood stream infections: a retrospective cohort study